NanoString Technologies Inc. entered into a collaboration agreement with Merck, through a subsidiary, to develop and commercialize a novel diagnostic assay to predict response to Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy. Under the terms of the collaboration agreement, NanoString will be responsible for seeking regulatory approval for and commercialization of the diagnostic test. NanoString will be...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
